The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics
UF startup Dialectic Therapeutics, in partnership with the Fibrolamellar Cancer Foundation (FCF), will supply the experimental drug DT2216 for a clinical trial involving fibrolamellar patients.
